Gary M. Clark
Impact in
- Oncology top 0.01%
- HER2/EGFR in Cancer Research
- Pancreatic and Hepatic Oncology Research
- Cancer-related Molecular Pathways
- Cancer Research top 0.01%
- Breast Cancer Treatment Studies
- Cancer Genomics and Diagnostics
Papers in
- Oncology 105
- HER2/EGFR in Cancer Research 39
- Cancer Treatment and Pharmacology 19
-
- Breast Cancer Treatment Studies 49
- Cancer Genomics and Diagnostics 16
- Co-authors
- William McGuire (44 shared papers)Dennis J. Slamon (2 shared papers)Axel Ullrich (1 shared paper)Steven Wong (1 shared paper)Wendy J. Levin (1 shared paper)C. Kent Osborne (29 shared papers)D. Craig Allred (37 shared papers)Lisa M. McShane (8 shared papers)
- Journals
- Journal of Clinical Oncology (30 papers)Breast Cancer Research and Treatment (26 papers)JNCI Journal of the National Cancer Institute (20 papers)Cancer (13 papers)Investigational New Drugs (7 papers)
- Partner nations
- United StatesCanadaUnited Kingdom
In The Last Decade
Gary M. Clark
269 papers receiving 43.3k citations
Gary M. Clark's Hit Papers
Peers
Comparison fields: 5 of 180
- Oncology 21.6k
- Cancer Research 11.5k
- Pulmonary and Respiratory Medicine 8.0k
- Radiology, Nuclear Medicine and Imaging 5.4k
- Pathology and Forensic Medicine 3.2k
Countries citing papers authored by Gary M. Clark
This map shows the geographic impact of Gary M. Clark's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gary M. Clark with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gary M. Clark more than expected).
Fields of papers citing papers by Gary M. Clark
This network shows the impact of papers produced by Gary M. Clark. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gary M. Clark. The network helps show where Gary M. Clark may publish in the future.
Co-authors
The 25 scholars most cited alongside Gary M. Clark, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 273 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/neuOncogene Hit paper breakdown → | 1987 | 9382 |
| 2 | Erlotinib in Previously Treated Non–Small-Cell Lung Cancer Hit paper breakdown → | 2005 | 4289 |
| 3 | Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group Hit paper breakdown → | 2007 | 2920 |
| 4 | Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK) Hit paper breakdown → | 2005 | 1705 |
| 5 | Estrogen Receptor Status by Immunohistochemistry Is Superior to the Ligand-Binding Assay for Predicting Response to Adjuvant Endocrine Therapy in Breast Cancer Hit paper breakdown → | 1999 | 1632 |
| 6 | REporting recommendations for tumour MARKer prognostic studies (REMARK) Hit paper breakdown → | 2005 | 1050 |
| 7 | Determinants of Tumor Response and Survival With Erlotinib in Patients With Non—Small-Cell Lung Cancer Hit paper breakdown → | 2004 | 893 |
| 8 | Revision of the American Joint Committee on Cancer Staging System for Breast Cancer Hit paper breakdown → | 2002 | 887 |
| 9 | Prognostic Factors in Breast Cancer Hit paper breakdown → | 2000 | 842 |
| 10 | Association of p53 Protein Expression With Tumor Cell Proliferation Rate and Clinical Outcome in Node-Negative Breast Cancer Hit paper breakdown → | 1993 | 686 |
| 11 | REporting recommendations for tumor MARKer prognostic studies (REMARK) Hit paper breakdown → | 2006 | 662 |
| 12 | Role of the Estrogen Receptor Coactivator AIB1 (SRC-3) and HER-2/neu in Tamoxifen Resistance in Breast Cancer Hit paper breakdown → | 2003 | 645 |
| 13 | Reporting Recommendations for Tumor Marker Prognostic Studies Hit paper breakdown → | 2005 | 617 |
| 14 | Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome Hit paper breakdown → | 2004 | 617 |
| 15 | Progesterone Receptor Status Significantly Improves Outcome Prediction Over Estrogen Receptor Status Alone for Adjuvant Endocrine Therapy in Two Large Breast Cancer Databases Hit paper breakdown → | 2003 | 567 |
| 16 | HER-2/neu oncogene protein and prognosis in breast cancer. Hit paper breakdown → | 1989 | 496 |
| 17 | Prediction of Relapse or Survival in Patients with Node-Negative Breast Cancer by DNA Flow Cytometry Hit paper breakdown → | 1989 | 467 |
| 18 | HER-2/neu amplification predicts poor survival in node-positive breast cancer. | 1990 | 392 |
| 19 | 1992 | 385 | |
| 20 | 1990 | 383 |
About Gary M. Clark
Gary M. Clark is a scholar working on Oncology, Cancer Research, Molecular Biology, Genetics and Pulmonary and Respiratory Medicine, having authored 273 papers that have together received 44.6k indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (49 papers), HER2/EGFR in Cancer Research (39 papers), Estrogen and related hormone effects (28 papers), Lung Cancer Treatments and Mutations (21 papers), Cancer Treatment and Pharmacology (19 papers), Statistical Methods in Clinical Trials (17 papers), Cancer Genomics and Diagnostics (16 papers) and Monoclonal and Polyclonal Antibodies Research (12 papers). The work is most often cited by research in Oncology (21.6k citations), Cancer Research (11.5k citations), Pulmonary and Respiratory Medicine (8.0k citations), Radiology, Nuclear Medicine and Imaging (5.4k citations) and Pathology and Forensic Medicine (3.2k citations). Gary M. Clark has collaborated with scholars based in United States, Canada and United Kingdom. Frequent co-authors include William McGuire, Dennis J. Slamon, Axel Ullrich, Steven Wong, Wendy J. Levin, C. Kent Osborne, D. Craig Allred, Lisa M. McShane, Sheila E. Taube and Massimo Gion. Their work appears in journals such as Journal of Clinical Oncology, Breast Cancer Research and Treatment, JNCI Journal of the National Cancer Institute, Cancer and Investigational New Drugs.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.